EnerSyn Global Inc. ESYN
Other Pharmaceuticals · IPO 2022 · data as of November 13, 2026
EnerSyn Global Inc. (ESYN) is a healthcare company listed in the US with a market value of about $37M. In the twelve months to September 30, 2026 it had revenue of $255606 and net income of -$5M, a net margin of -2095.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -53%.
About EnerSyn Global
EnerSyn Global is listed in the US and classified in other pharmaceuticals, IPO year 2022. It was profitable in 1 of the last 4 years in our data.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $255606 | $866926 | $1M | $1184 | — |
| Net income | -$5M | -$3M | -$3M | -$1M | $113541 |
| Free cash flow | -$837442 | -$2M | -$2M | -$3M | — |
| EPS (diluted) | $-0.49 | $-0.40 | $-0.76 | — | — |
| Net margin | -2095.4% | -303.4% | -219.4% | -91257.8% | — |
| ROIC | — | -58.6% | -46.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does EnerSyn Global pay a dividend?
Not currently.
Is EnerSyn Global a good stock to buy?
We do not give buy or sell advice. EnerSyn Global scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.